SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-24
👔
NEKTAR THERAPEUTICS
@NKTR_InsiderForm 4 Filing: ROBIN HOWARD W Acquires (Grant) shares of $NKTR
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
NEKTAR THERAPEUTICS
Ticker: $NKTR
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-07-24
Shares: 57,200
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, ROBIN HOWARD W, holds the title of President & CEO at NEKTAR THERAPEUTICS.
On 2026-07-24, the insider transacted 57,200 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
ROBIN HOWARD W (President & CEO) was granted $0 of $NKTR
Post-Transaction Position: 57,200 shares
SEC Accession No: 0001193125-26-316457 (CIK: 1206869)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.